Market Overview:
Aptamers are small, single-stranded DNA or RNA molecules that bind to specific molecular targets such as protein, peptide, or small molecule ligands. They can be used for various diagnostic and therapeutic applications. Aptamers have various advantages over antibodies such as high affinity and specificity for targets, synthetic production without animals or immunization, long shelf life, and reversible binding.
Market Dynamics:
The aptamers market is driven by the rising prevalence of infectious diseases and various chronic diseases globally. According to WHO, infectious diseases account for approximately 26% of global deaths every year. The development of aptamers against various pathogens, toxins, and virulence factors for diagnostic and therapeutic applications is expected to boost market growth. Further, increasing R&D investments by key players for development of novel aptamer-based therapeutics and diagnostics is also anticipated to propel the market growth over the forecast period. However, high development costs and regulatory issues pertaining to clinical trials may hinder market growth.
The global Aptamers Market Share is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights
SWOT Analysis
Strength: Aptamers have high affinity and specificity for their target molecules. They can be easily produced through cell-free selection processes at relatively low cost. Aptamers have attractive pharmacokinetic properties such as small size, non-immunogenicity, and no batch-to-batch variability.
Weakness: The development and regulatory approval process for aptamers as drugs is complex and expensive. Also, their small size results in early renal clearance requiring modifications to improve their half-life.
Opportunity: The growing fields of personalized medicine and companion diagnostics provide major opportunities for aptamer applications. Also, the low production cost makes them suitable for low-income populations in developing countries.
Threats: Stringent regulations around the clinical use of aptamers may hinder their commercial adoption. Competing technologies such as monoclonal antibodies also pose challenges.
Key Takeaways
The global Aptamers market is expected to witness high growth, exhibiting CAGR of 18.% over the forecast period, due to increasing research and development activities in the field of personalized medicine and companion diagnostics. Aptamers are getting recognized as viable alternatives to antibodies and the low production cost makes them suitable for developing economies.
Regional analysis
North America dominated the global aptamers market in 2022 and is expected to maintain its dominance over the forecast period. This is attributed to increasing R&D investments and growing biotechnology industry in the region. However, Asia Pacific is expected to witness the fastest growth owing to rising healthcare expenditure, favorable government initiatives and growing biotech industry in countries like China and India.
Key players
Key players operating in the Aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Major players are focusing on expanding their product portfolios through collaborations and acquisitions to strengthen their market position.
Read More: https://blogger-veritas.blogspot.com/2023/12/aptamers-are-fastest-growing-segment.html
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian